743 related articles for article (PubMed ID: 14970148)
21. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection.
Ormaasen V; Bruun JN; Sandvik L; Holberg-Petersen M; Gaarder PI
Scand J Infect Dis; 2003; 35(6-7):383-8. PubMed ID: 12953949
[TBL] [Abstract][Full Text] [Related]
22. The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of < or = 50 x 10(6) cells/l.
Coakley EP; Samore MH; Gillis JM; Hughes MD; Hammer SM
AIDS; 2000 Jun; 14(9):1147-53. PubMed ID: 10894278
[TBL] [Abstract][Full Text] [Related]
23. The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use.
Kapadia F; Cook JA; Cohen MH; Sohler N; Kovacs A; Greenblatt RM; Choudhary I; Vlahov D
Addiction; 2005 Jul; 100(7):990-1002. PubMed ID: 15955015
[TBL] [Abstract][Full Text] [Related]
24. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
[TBL] [Abstract][Full Text] [Related]
25. The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women's interagency HIV study.
DeHovitz JA; Kovacs A; Feldman JG; Anastos K; Young M; Cohen M; Gange SJ; Melnick S; Greenblatt RM
J Infect Dis; 2000 Nov; 182(5):1527-30. PubMed ID: 11010840
[TBL] [Abstract][Full Text] [Related]
26. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
[TBL] [Abstract][Full Text] [Related]
27. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.
Li X; Margolick JB; Jamieson BD; Rinaldo CR; Phair JP; Jacobson LP
J Acquir Immune Defic Syndr; 2011 Aug; 57(5):421-8. PubMed ID: 21602699
[TBL] [Abstract][Full Text] [Related]
28. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
[TBL] [Abstract][Full Text] [Related]
30. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
[TBL] [Abstract][Full Text] [Related]
31. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
32. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
33. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy.
Anastos K; Shi Q; French AL; Levine A; Greenblatt RM; Williams C; DeHovitz J; Delapenha R; Hoover DR
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):383-92. PubMed ID: 15097155
[TBL] [Abstract][Full Text] [Related]
34. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
35. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
36. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
[TBL] [Abstract][Full Text] [Related]
37. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
38. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART.
Lapadula G; Chatenoud L; Gori A; Castelli F; Di Giambenedetto S; Fabbiani M; Maggiolo F; Focà E; Ladisa N; Sighinolfi L; Di Pietro M; Pan A; Torti C;
PLoS One; 2015; 10(5):e0124741. PubMed ID: 26020949
[TBL] [Abstract][Full Text] [Related]
39. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
40. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
van Lelyveld SF; Gras L; Kesselring A; Zhang S; De Wolf F; Wensing AM; Hoepelman AI;
AIDS; 2012 Feb; 26(4):465-74. PubMed ID: 22112603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
